India unveils world's first nasal vaccine for Covid (Photo for representation)
The booster dose of Bharat Biotech’s Covid-19 nasal vaccine iNCOVACC was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI).
The EUA is reported to have been granted for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.
According to the Hyderabad-based vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.
iNCOVACC is India’s first nasal vaccine developed against Covid-19. The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.
The intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus. The booster dose will thereby protect against disease, infection, and transmission.
Indian High Commissioner to Australia, Gopal Baglay on Monday called on the Australian Foreign Minister,…
The 4th Session of the India-Ghana Joint Trade Committee (JTC) concluded in Accra, with both…
In a swift and coordinated sea-air operation, the Indian Coast Guard intercepted and detained an…
The United Nations Assistance Mission in Afghanistan (UNAMA) reports that a staggering 23.7 million people…
Israel's military has issued an urgent evacuation notice to residents of eastern Rafah, following a…
Indian-origin astronaut Captain Sunita Williams and her fellow veteran NASA astronaut Butch Wilmore are set…